APP13007 is designed to address post-operative inflammation and pain after ocular surgery. Credit: Antonio Guillem/Shutterstock.

Formosa Pharmaceuticals in Taiwan has signed an exclusive licensing agreement with Medvisis Switzerland to commercialise clobetasol propionate ophthalmic suspension, 0.05% (APP13007), for post-operative inflammation and pain after ocular surgery.

The agreement grants Medvisis exclusive rights for the therapy in Switzerland and Liechtenstein.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

APP13007 received approval from the US Food and Drug Administration in March 2024.

The deal between Formosa and Medvisis includes upfront payments, sales milestones and additional considerations throughout the term period.

Formosa Pharmaceuticals CEO and president Erick Co stated: “We are pleased to partner with Medvisis, marking our second foothold in Europe.

“Medvisis’ strong connections with their national regulatory agency and rich KOL [key opinion leaders] network give us great confidence that the Swiss public will benefit from this novel and effective treatment for ocular surgery recovery.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

APP13007 features the active ingredient superpotent corticosteroid clobetasol propionate, and is based on Formosa’s APNT [active pharmaceutical nanotechnology] nanoparticle formulation platform.

The therapy’s formulation allows for a twice-daily dosing regimen for 14 days, providing rapid and sustained relief. It was launched in the US market in September 2024.

A US survey of 100 ophthalmic surgeons highlighted the rapid resolution of pain, with 80% of patients pain-free four days post-surgery, and a low incidence of adverse events, less than 2%, as key factors.

In August 2024, Formosa signed an exclusive licencing agreement with Apotex for the commercialisation of APP13007.

Medvisis Switzerland CEO Manuel Ackermann stated: “We are pleased to provide patients with post-operative inflammation and pain following ocular surgery a new, best-in-class treatment option that leads to faster symptom relief.

“APP13007 is of great value to Swiss patients, while it sets the foundation for Medvisis to build a strong portfolio of innovative ophthalmology solutions.”